ADORA2A and in situ carcinoma: The combination of cisplatin with treatments (CIS + CA and CIS + BM) increased A2A receptors and decreased CD73-positive cells, suggesting an inhibitor effect of the compounds, reinforcing the hypothesis that restraining the adenosine pathway by blocking the A2AR signaling pathway or reducing its production may increase the activity of anti-CTLA4 inhibitors and apoptosis [91,92].